高级检索
当前位置: 首页 > 详情页

Seven key hub genes identified by gene co-expression network in cutaneous squamous cell carcinoma.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]School of Basic Medical Sciences, Dali University, Dali, Yunnan 671000,People’s Republic of China [2]Institute of Translational Medicine for MetabolicDiseases, Dali University, Dali, Yunnan 671000, People’s Republic of China [3]Department of Dermatology, First Affiliated Hospital of Kunming MedicalUniversity, Kunming, Yunnan 650000, People’s Republic of China
出处:
ISSN:

摘要:
Cutaneous squamous cell carcinoma (cSCC) often follows actinic keratosis (AK) and is the second most common skin cancer worldwide. To reduce metastasis risk, it is important to diagnose and treat cSCC early. This study aimed to identify hub genes associated with cSCC and AK.This study used three datasets GSE45216, GSE98774, and GSE108008. We combined samples from the GSE45216 and GSE98774 datasets into the new dataset GSE45216-98774. We applied a weighted gene co-expression network analysis (WGCNA) to investigate key modules and hub genes associated with cSCC and AK. We considered the hub genes found in both the GSE45216-98774 and GSE108008 datasets as validated hub genes. We tested whether the expression of hub genes could predict patient survival outcomes in other cancers using TCGA pan-cancer data.We identified modules most relevant to cSCC and AK. Additionally, we identified and validated seven hub genes of cSCC: GATM, ARHGEF26, PTHLH, MMP1, POU2F3, MMP10 and GATA3. We did not find validated hub genes for AK. Each hub gene was significantly associated with the survival of various cancer types. Only GATA3 was significantly associated with melanoma survival.We applied WGCNA to find seven hub genes that play important roles in cSCC tumorigenesis. These results provide new insights that help explain the pathogenesis of cSCC. These hub genes may become biomarkers or therapeutic targets for accurate diagnosis and treatment of cSCC in the future.© 2021. The Author(s).

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 2 区 医学
小类 | 3 区 肿瘤学
最新[2023]版:
大类 | 2 区 医学
小类 | 3 区 肿瘤学
JCR分区:
出版当年[2021]版:
Q2 ONCOLOGY
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]School of Basic Medical Sciences, Dali University, Dali, Yunnan 671000,People’s Republic of China [2]Institute of Translational Medicine for MetabolicDiseases, Dali University, Dali, Yunnan 671000, People’s Republic of China
通讯作者:
通讯机构: [1]School of Basic Medical Sciences, Dali University, Dali, Yunnan 671000,People’s Republic of China [2]Institute of Translational Medicine for MetabolicDiseases, Dali University, Dali, Yunnan 671000, People’s Republic of China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:52537 今日访问量:0 总访问量:1562 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)